GlobeNewsWire
03 Nov 2025, 21:02 UTC · 45w ago
Verdict
Headline takes no side. We score FGEN +0.20 across three claims — slightly bullish.
+0.20slightly bullish
More positive than 47% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
FibroGen will report its third quarter 2025 financial results on November 10 after market close.
More positive than 62% of claims this week
A post hoc analysis of roxadustat showed durable and clinically meaningful improvement in transfusion independence for patients with LR-MDS and high transfusion burden.
So whatPositive clinical data supports the potential for U.S. approval in a new indication, increasing long-term valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 50% of claims this week
The Phase 2 monotherapy trial of FG-3246 for metastatic castration-resistant prostate cancer is progressing well.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 47% of ticker scores this week
The company announced upcoming earnings and reported positive progress in its drug development pipeline and clinical analysis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
54m ago
Seeking Alpha
3h ago
−17.6%
Price is moving against the score
$9.07 vs $11.01 close before publication (Nov 3) · not market-adjusted
FGEN chart →
